Augmented cytotoxicity of estramustine and etoposide combination in hormone refractory prostate cancer cell lines and association with TGF modulation

被引：0
作者：
LN Türkeri
O Ayaz
M Özyürek
A Akdas
机构：
[1] ‘Ergun Özalp’ Research Laboratory,Department of Urology
[2] Marmara University School of Medicine,undefined
来源：
Prostate Cancer and Prostatic Diseases | 1999年 / 2卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：S33 / S33
相关论文
共 50 条
  • [31] Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma
    Smith, DC
    Chay, CH
    Dunn, RL
    Fardig, J
    Esper, P
    Olson, K
    Pienta, KJ
    [J]. CANCER, 2003, 98 (02) : 269 - 276
  • [32] ORAL ETOPOSIDE IN THE TREATMENT OF HORMONE-REFRACTORY PROSTATE-CANCER
    HUSSAIN, MH
    PIENTA, KJ
    REDMAN, BG
    CUMMINGS, GD
    FLAHERTY, LE
    [J]. CANCER, 1994, 74 (01) : 100 - 103
  • [33] Induction of apoptosis in human hormone-refractory prostate cancer cell lines by using resveratrol in combination with AT-101
    Aktepe, Necmettin
    Yukselten, Yunus
    [J]. ANDROLOGIA, 2022, 54 (01)
  • [34] Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients
    Soga, Norihito
    Kato, Manabu
    Nishikawa, Kouhei
    Hasegawa, Yoshihiro
    Yamada, Yasushi
    Kise, Hideaki
    Arima, Kiminobu
    Sugimura, Yoshiki
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2009, 14 (02) : 130 - 135
  • [35] Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)
    Joseph G. Kattan
    Fady S. Farhat
    Georges Y. Chahine
    Fady L. Nasr
    Walid T. Moukadem
    Fariha C. Younes
    Nadine J. Yazbeck
    Marwan G. Ghosn
    [J]. Investigational New Drugs, 2008, 26 : 75 - 79
  • [36] Marked leukocytosis in response to estramustine phosphate in a hormone-refractory prostate cancer patient
    Morita, Tatsuo
    [J]. INTERNATIONAL MEDICAL CASE REPORTS JOURNAL, 2010, 3 : 39 - 41
  • [37] Combination therapy in hormone-refractory prostate cancer
    Daniel P. Petrylak
    [J]. Current Oncology Reports, 2001, 3 (5) : 453 - 453
  • [38] Docetaxel in Combination with Prednisolone for Hormone Refractory Prostate Cancer
    Ide, Hiroki
    Kikuchi, Eiji
    Kono, Hidaka
    Nagata, Hirohiko
    Miyajima, Akira
    Nakagawa, Ken
    Ohigashi, Takashi
    Nakashima, Jun
    Oya, Mototsugu
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (01) : 79 - 84
  • [39] Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients
    Norihito Soga
    Manabu Kato
    Kouhei Nishikawa
    Yoshihiro Hasegawa
    Yasushi Yamada
    Hideaki Kise
    Kiminobu Arima
    Yoshiki Sugimura
    [J]. International Journal of Clinical Oncology, 2009, 14 : 130 - 135
  • [40] Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)
    Kattan, Joseph G.
    Farhat, Fady S.
    Chahine, Georges Y.
    Nasr, Fady L.
    Moukadem, Walid T.
    Younes, Fariha C.
    Yazbeck, Nadine J.
    Ghosn, Marwan G.
    [J]. INVESTIGATIONAL NEW DRUGS, 2008, 26 (01) : 75 - 79
12345